BTIG Maintains Buy on DexCom, Raises Price Target to $96
BTIG analyst Ryan Zimmerman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $96.
Share
Why It Matters
An analyst who studies DexCom believes the company is worth more money now. This usually means the analyst thinks DexCom is doing well and will keep growing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.